Dr. Reddy's Active Pharmaceutical Ingredients

What Dr. Reddy's Active Pharmaceutical Ingredients does

Dr. Reddy's Active Pharmaceutical Ingredients is the API manufacturing and supply division of Dr. Reddy's Laboratories Ltd., a publicly traded pharmaceutical company (BSE/NSE) headquartered in Hyderabad, India, founded in 1984. The API business produces and supplies more than 250 active pharmaceutical ingredients to generic drug manufacturers across 80+ countries, backed by 2,000+ Drug Master Files (DMFs) filed globally. The division operates 8 cGMP-compliant manufacturing facilities (6 in India, 1 in Mexico, 1 in the UK), all of which have undergone inspection by major regulatory agencies including the US FDA.

The business is organized around four core offerings: (1) API Solutions, the core commercial manufacturing and supply franchise; (2) Generic Formulations, sold B2B to other drug makers; (3) Strategic Alliances, encompassing licensing and technology transfer arrangements with innovator pharma companies; and (4) Discovery & CDMO services delivered through Aurigene, a subsidiary formed in 2020 that consolidated the parent company's discovery, development, and contract research assets. Aurigene also operates the Aurigene.AI platform, which combines generative AI, predictive modeling, computational chemistry, and CADD/bioinformatics tools, and is supported by a virtual compound library of more than 12 billion molecules.

Revenue is generated through B2B supply agreements with generic formulation manufacturers, licensing royalties, technology-transfer fees, and CDMO contracts. Notable commercial relationships include manufacturing and supply arrangements with Gilead Sciences (remdesivir), FUJIFILM and Global Response Aid (Avigan for COVID-19), and Industrial Promotion Services for the East African Combined Pharmaceutical Center in Kenya. The parent company reported approximately $3.8B in revenue; the API business is one of several operating segments alongside branded generics and biosimilars, and segment-level financials for the API division alone are not separately disclosed in the available data.

Name

Dr. Reddy's Active Pharmaceutical Ingredients

Legal name

Dr. Reddy's Laboratories Ltd.

Website

https://api.drreddys.com

Company type

Public

Founded year

1984

Operating status

Operating

Headcount range

51–100 employees

Short description

Dr. Reddy's API business is the Active Pharmaceutical Ingredients division of Dr. Reddy's Laboratories, supplying 250+ APIs to global generic drug manufacturers across 80+ countries via 8 cGMP sites in India, Mexico, and the UK, with integrated CDMO services through subsidiary Aurigene.

Ownership category

akta.pro rank

Product category

Active Pharmaceutical Ingredients Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)

SIC

Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)

akta.pro industry

PRIMARYHLAGAHAB

Small-Molecule API Commercial Manufacturing

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

SECONDARYHLAGAHAL

GMP Scale-Up, Tech Transfer & Process Validation (PPQ)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

SECONDARYHLAGAHAM

Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

SECONDARYHLAIABAG

Generic APIs & Intermediates (Active Ingredients)

Healthcare & Life Sciences/Pharmaceuticals/Generic Pharmaceuticals

Keywords

• Active pharmaceutical ingredients
• API manufacturing
• Generic drug formulations
• Contract research development manufacturing
• Drug master filings

Headquarters

HQ city

Hyderabad

HQ country

India

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. API Sales: Sale of Active Pharmaceutical Ingredients to generic formulations manufacturers across 80+ countries. The company offers 250+ affordable, high-quality APIs, focusing on first-to-market and hard-to-make products.
2. Generic Formulations (B2B): Supply of finished products to partners for distribution and commercialization. Market-specific, customizable dossiers meet local regulatory requirements. Includes formulation, tech transfer, and pre-formulation supplies.
3. Discovery & CDMO Services (Aurigene): Integrated services across key starting materials, intermediates, APIs, and finished dosage forms from lab to market. CRDMO services including contract manufacturing and drug discovery for global pharma and biotech companies.
4. Strategic Alliances: In-licensing and out-licensing arrangements, tech transfer services, and strategic partnerships to expand portfolio and bring innovative treatments to market efficiently.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

Dr. Reddy's API business manufactures and supplies high-quality, affordable Active Pharmaceutical Ingredients (APIs) to generic formulations manufacturers in 80+ countries. The company offers 250+ APIs with focus on first-to-market and hard-to-make molecules, supported by cGMP (ICH Q7) compliant manufacturing across 8 sites globally (6 in India, 1 in Mexico, 1 in UK) and 2,000+ Drug Master Files filed worldwide.

Product overview

Dr. Reddy's API business is a leading manufacturer and supplier of Active Pharmaceutical Ingredients (APIs) operating as a multi-product pharmaceutical company. The core offering is API Solutions - a portfolio of 250+ high-quality APIs supplied to generic formulations manufacturers across 80+ countries. Complementing the core API business are four additional offerings: Generic Formulations (B2B) for finished product supply, Strategic Alliances for licensing and tech transfer services, Discovery & CDMO (Aurigene) for contract development and manufacturing, and Aurigene.AI for AI-driven drug discovery services. The company operates 8 API manufacturing sites (6 in India, 1 in Mexico, 1 in UK) and has filed 2000+ DMFs globally.

Differentiator

Problem solved

Functional benefit

Brands

• Aurigene.AI: AI-driven drug discovery platform leveraging cutting-edge tools like CADD and bioinformatics, featuring virtual library of 12+ billion compounds called Aurimine
• Aurigene Discovery & CDMO
• XCEED

Products and services

• API Solutions A portfolio of 250+ high-quality, affordable Active Pharmaceutical Ingredients (APIs) supplied to leading generic formulations manufacturers across 80+ countries, with focus on first-to-market and hard-to-make molecules. Customers include pharmaceutical companies needing API supply for commercial and R&D purposes.
• Generic Formulations (B2B) B2B formulations business supplying finished pharmaceutical products to distribution partners for commercialization in markets where Dr. Reddy's has no direct presence. Includes market-specific customizable dossiers meeting local regulatory requirements, along with formulation, tech transfer, and pre-formulation supplies.
• Strategic Alliances Strategic in-licensing and out-licensing services with comprehensive tech transfer capabilities enabling faster development, local manufacturing, and regulatory success for global pharma partners. Includes partnerships to bring innovative treatments to market efficiently.
• Discovery & CDMO (Aurigene) Contract Research, Development and Manufacturing Organization (CRDMO) subsidiary offering integrated services across key starting materials, intermediates, APIs, and finished dosage forms from lab to market, serving global pharma and biotech companies.
• Aurigene.AI AI-driven drug discovery platform integrating predictive, generative, and computational models with a validated compound database to streamline candidate identification for global pharma and biotech partners.

Quantifiable outcome

• First company to receive Health Canada marketing authorization for generic Semaglutide Injection in Canada
• +2 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Partnerships

Five partnerships are on record, tiered core.

• Lenacapavir License PartnercoreStrategic or Co-development Partner · 10 October 2025Bold Leap for Global HIV Prevention: Lenacapavir Agreement Signed. Partnership to advance global access to lenacapavir for HIV treatment and prevention.
• Industrial Promotion Services (IPS)coreStrategic or Co-development Partner · 5 April 2024Strategic collaboration with Industrial Promotion Services (IPS) to support the East African Combined Pharmaceutical Center (EACPC) in Kenya. This partnership aims to strengthen pharmaceutical manufacturing capabilities in East Africa through technology transfer and capacity building.
• FUJIFILM and Global Response AidcoreStrategic or Co-development Partner · 1 July 2020Partnership with FUJIFILM and Global Response Aid for Avigan (favipiravir), a potential treatment for COVID-19. Dr. Reddy's developed Redyx formulation under license from Gilead.
• Aurigene (Subsidiary of Dr. Reddy's)coreStrategic or Co-development PartnerAurigene is a subsidiary of Dr. Reddy's formed in 2020 by consolidating service businesses into a customer-centric organization. Offers integrated CRDMO services across key starting materials, intermediates, APIs, and finished dosage forms. Leverages Aurigene.AI platform with 12+ billion compound virtual library for drug discovery.
• Gilead SciencescoreOEM/ Whitelabel/ Licensing PartnerLicensed from Gilead for Redyx (Remdesivir) formulation development. Dr. Reddy's developed the Redyx formulation under the license from Gilead for COVID-19 treatment.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Cipla Limited: Cipla is a leading Indian pharmaceutical manufacturer with significant API production capabilities alongside its branded and generic finished-dose global business. Both companies leverage Indian manufacturing scale and global regulatory expertise to serve generic pharma customers worldwide.
• Sun Pharmaceutical Industries: Sun Pharma is India's largest pharmaceutical company with significant API manufacturing operations alongside a much larger branded and generic finished-dose business. Both companies share Indian heritage, USFDA-inspected facilities, and global generic customer reach, though Sun's portfolio is substantially broader.
• Lupin Limited: Lupin is a major Indian pharmaceutical company with integrated API and finished-dose operations serving global generic customers, particularly in the US and Europe. The company operates comparable cGMP manufacturing facilities and pursues a similar strategy of vertical integration between APIs and finished generics.
• Teva Pharmaceutical Industries: Teva is the world's largest generic drug manufacturer with vertically integrated API production from its own manufacturing network supplying both internal and external customers. While headquartered in Israel rather than India, Teva competes with Dr. Reddy's for global generic API and finished-dose customers.
• Sandoz Group: Sandoz, recently spun out of Novartis, is one of the world's largest generics manufacturers with substantial API manufacturing capabilities. The company competes directly with Dr. Reddy's in supplying generic APIs and finished-dose products to global customers, particularly in Europe and the US.

Direct peers

• Divi's Laboratories: Divi's is a pure-play Indian API manufacturer and custom synthesis CDMO with comparable capabilities in complex small-molecule APIs and intermediates for global innovator and generic customers. Both companies operate cGMP-compliant Indian facilities supplying APIs into US/EU markets with similar regulatory filing depth.
• Aurobindo Pharma: Aurobindo Pharma is one of India's largest API and generic formulations manufacturers, with a comparable 200+ molecule API portfolio serving global generic customers. Both companies compete head-to-head in the global generic API market with similar USFDA-inspected manufacturing footprints and a focus on cost-efficient large-scale API production.
• Laurus Labs: Laurus Labs is an Indian-headquartered API manufacturer focused on high-quality APIs for antiretroviral, oncology, and cardiovascular therapies sold globally to generic and branded customers. The business model, customer profile, and end-market focus closely mirror Dr. Reddy's API franchise.
• Aarti Pharmalabs: Aarti Pharmalabs is an Indian API manufacturer with a comparable portfolio of high-quality APIs and intermediates serving global pharmaceutical customers. Both companies target similar therapeutic segments (cardiovascular, CNS, anti-infectives) and compete for global generic customer relationships.

Emerging players

• Piramal Pharma Limited: Piramal Pharma offers integrated CDMO services with capabilities in API manufacturing, formulations, and biologics development. While more diversified than Dr. Reddy's pure API business, Piramal's CDMO arm competes for similar global pharma partnership contracts and customer relationships.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/drreddys
• YouTubeyoutube.com/drreddys
• Facebookfacebook.com/Dr.ReddysLaboratoriesLtd
• LinkedInlinkedin.com/company/dr-reddys-api

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dr. Reddy's Active Pharmaceutical Ingredients